- Home
- FIGS vs IMNM Comparison
FIGS vs IMNM Comparison
Compare FIGS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- IMNM
- Stock Information
- Founded
- FIGS 2013
- IMNM 2006
- Country
- FIGS United States
- IMNM United States
- Employees
- FIGS N/A
- IMNM N/A
- Industry
- FIGS Apparel
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- FIGS Consumer Discretionary
- IMNM Health Care
- Exchange
- FIGS Nasdaq
- IMNM Nasdaq
- Market Cap
- FIGS 881.3M
- IMNM 747.7M
- IPO Year
- FIGS 2021
- IMNM 2020
- Fundamental
- Price
- FIGS $5.76
- IMNM $10.97
- Analyst Decision
- FIGS Hold
- IMNM Strong Buy
- Analyst Count
- FIGS 6
- IMNM 5
- Target Price
- FIGS $5.35
- IMNM $28.60
- AVG Volume (30 Days)
- FIGS 3.0M
- IMNM 911.8K
- Earning Date
- FIGS 11-07-2024
- IMNM 11-13-2024
- Dividend Yield
- FIGS N/A
- IMNM N/A
- EPS Growth
- FIGS N/A
- IMNM N/A
- EPS
- FIGS 0.05
- IMNM N/A
- Revenue
- FIGS $548,644,000.00
- IMNM $10,129,000.00
- Revenue This Year
- FIGS $1.64
- IMNM N/A
- Revenue Next Year
- FIGS $3.07
- IMNM N/A
- P/E Ratio
- FIGS $104.62
- IMNM N/A
- Revenue Growth
- FIGS 0.55
- IMNM N/A
- 52 Week Low
- FIGS $4.30
- IMNM $8.33
- 52 Week High
- FIGS $7.98
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- FIGS 54.34
- IMNM 39.61
- Support Level
- FIGS $5.47
- IMNM $10.76
- Resistance Level
- FIGS $6.23
- IMNM $15.13
- Average True Range (ATR)
- FIGS 0.33
- IMNM 0.98
- MACD
- FIGS 0.06
- IMNM -0.29
- Stochastic Oscillator
- FIGS 56.99
- IMNM 4.81
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company markets and sells its products in the United States. Sales are generated through the Company's digital platforms.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.